X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (736) 736
oncology (725) 725
index medicus (659) 659
chemotherapy (503) 503
lung neoplasms - drug therapy (387) 387
carcinoma, non-small-cell lung - drug therapy (371) 371
cancer (367) 367
female (338) 338
antineoplastic combined chemotherapy protocols - therapeutic use (312) 312
phase-iii trial (280) 280
aged (252) 252
care and treatment (243) 243
male (235) 235
middle aged (234) 234
lung cancer, non-small cell (224) 224
lung cancer (216) 216
open-label (208) 208
lung neoplasms - pathology (206) 206
bevacizumab (204) 204
carboplatin (189) 189
treatment outcome (189) 189
antineoplastic agents - therapeutic use (188) 188
paclitaxel (188) 188
1st-line treatment (184) 184
carcinoma, non-small-cell lung - pathology (183) 183
adult (179) 179
cisplatin (154) 154
non-small cell lung cancer (153) 153
phase-ii trial (146) 146
research (143) 143
carboplatin - administration & dosage (134) 134
neoplasm staging (132) 132
respiratory system (132) 132
clinical trials (129) 129
medicine & public health (127) 127
pharmacology & pharmacy (127) 127
survival (126) 126
double-blind (122) 122
hematology, oncology and palliative medicine (122) 122
randomized-trial (119) 119
antineoplastic combined chemotherapy protocols - adverse effects (118) 118
cisplatin plus gemcitabine (118) 118
cell lung-cancer (117) 117
metastasis (117) 117
cancer therapies (115) 115
lung neoplasms - mortality (113) 113
drug therapy (110) 110
mutation (110) 110
aged, 80 and over (109) 109
paclitaxel - administration & dosage (109) 109
carcinoma, non-small-cell lung - mortality (106) 106
trial (100) 100
gemcitabine (99) 99
health aspects (99) 99
disease-free survival (98) 98
randomized controlled trials as topic (98) 98
prognosis (97) 97
docetaxel (95) 95
endothelial growth-factor (95) 95
gefitinib (93) 93
survival rate (92) 92
erlotinib (88) 88
vinorelbine plus cisplatin (87) 87
analysis (84) 84
antineoplastic agents (82) 82
growth-factor receptor (81) 81
non-small-cell lung cancer (81) 81
patients (81) 81
tumors (80) 80
vascular endothelial growth factor (80) 80
angiogenesis (79) 79
antimitotic agents (79) 79
lung neoplasms - genetics (77) 77
1st-line therapy (76) 76
clinical trials as topic (76) 76
nsclc (76) 76
platinum-based chemotherapy (76) 76
angiogenesis inhibitors - therapeutic use (75) 75
carcinoma (75) 75
phase-iii (75) 75
carcinoma, non-small-cell lung - genetics (74) 74
survival analysis (74) 74
therapy (74) 74
plus carboplatin (73) 73
review (72) 72
ovarian cancer (71) 71
combination (70) 70
immunotherapy (70) 70
supportive care (69) 69
deoxycytidine - analogs & derivatives (68) 68
randomized phase-iii (68) 68
receptor, epidermal growth factor - antagonists & inhibitors (68) 68
cisplatin - administration & dosage (67) 67
cooperative-oncology-group (67) 67
protein kinase inhibitors - therapeutic use (67) 67
animals (66) 66
antineoplastic combined chemotherapy protocols - administration & dosage (66) 66
molecular targeted therapy (66) 66
quality-of-life (66) 66
retrospective studies (65) 65
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lung Cancer, ISSN 0169-5002, 2011, Volume 76, Issue 3, pp. 362 - 367
Journal Article
Oncology Research and Treatment, ISSN 2296-5270, 11/2018, Volume 41, Issue 12, pp. 736 - 743
Journal Article
Journal Article
Annals of Oncology, ISSN 0923-7534, 07/2011, Volume 22, Issue 7, pp. 1520 - 1527
Journal Article
Oral Oncology, ISSN 1368-8375, 2015, Volume 53, pp. 54 - 59
Journal Article
Journal for ImmunoTherapy of Cancer, ISSN 2051-1426, 11/2017, Volume 5, Issue 1, pp. 83 - 13
Journal Article
Journal Article
Investigational New Drugs, ISSN 0167-6997, 12/2014, Volume 32, Issue 6, pp. 1188 - 1196
Purpose Preclinical evidence supports synergy between the vascular disrupting agent ombrabulin and various chemotherapy agents. Ombrabulin was combined with... 
Chemotherapy | Ombrabulin | Medicine & Public Health | Platinum | Oncology | Taxane | Pharmacology/Toxicology | Vascular disrupting agent | COMBINATION | DOCETAXEL | PACLITAXEL | TRIAL | CISPLATIN | ONCOLOGY | OVARIAN | PHARMACOLOGY & PHARMACY | PLUS | Neoplasms - metabolism | Cisplatin - pharmacokinetics | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Serine - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Response Evaluation Criteria in Solid Tumors | Carboplatin - pharmacokinetics | Paclitaxel - pharmacokinetics | Cisplatin - administration & dosage | Carboplatin - adverse effects | Young Adult | Drug Interactions | Adult | Female | Paclitaxel - administration & dosage | Taxoids - adverse effects | Serine - analogs & derivatives | Docetaxel | Carboplatin - administration & dosage | Paclitaxel - adverse effects | Neoplasms - drug therapy | Taxoids - pharmacokinetics | Taxoids - administration & dosage | Serine - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Cisplatin - adverse effects | Aged | Serine - adverse effects | Antimitotic agents | Pharmacology | Dosage and administration | Research | Drug therapy, Combination | Drug therapy | Pharmacokinetics | Antineoplastic agents | Methods | Tumors | Studies | Clinical trials | Medical research | Cancer therapies | Pharmaceutical sciences | Index Medicus
Journal Article
Anti-Cancer Drugs, ISSN 0959-4973, 10/2011, Volume 22, Issue 9, pp. 926 - 932
The combination of carboplatin/paclitaxel is commonly used as chemotherapy for advanced non-small cell lung cancer. However, the relatively high incidence of... 
non-small cell lung cancer | pharmacokinetics | paclitaxel | neurotoxicity | chemotherapy | current perception threshold | MULTICENTER | COLONY-STIMULATING FACTOR | ONCOLOGY-GROUP TRIAL | RANDOMIZED-TRIAL | STAGE-IIIB | PHASE-II TRIAL | TAXOL-INDUCED NEUROPATHY | ONCOLOGY | METASTATIC BREAST-CANCER | PHARMACOLOGY & PHARMACY | PACLITAXEL PLUS CARBOPLATIN | Carcinoma, Non-Small-Cell Lung - radiotherapy | Lung Neoplasms - drug therapy | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Lung Neoplasms - radiotherapy | Male | Carboplatin - pharmacokinetics | Paclitaxel - pharmacokinetics | Carboplatin - adverse effects | Carboplatin - therapeutic use | Peripheral Nervous System Diseases - prevention & control | Aged, 80 and over | Adult | Dose Fractionation | Female | Paclitaxel - administration & dosage | Drug Administration Schedule | Carboplatin - administration & dosage | Paclitaxel - adverse effects | Neurotoxicity Syndromes - prevention & control | Paclitaxel - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Aged | Combined Modality Therapy - methods | Carcinoma, Non-Small-Cell Lung - drug therapy | Index Medicus
Journal Article
Annals of Oncology, ISSN 0923-7534, 11/2009, Volume 20, Issue 11, pp. 1787 - 1793
Journal Article
American Journal of Clinical Oncology: Cancer Clinical Trials, ISSN 0277-3732, 02/2012, Volume 35, Issue 1, pp. 58 - 63
Objectives: The aim of the present study was to evaluate the efficacy and safety of carboplatin plus paclitaxel versus gemcitabine plus vinorelbine in patients... 
vinorelbine | paclitaxel | gemcitabine | performance status | carboplatin | nonsmall cell lung cancer | GEFITINIB | CHEMOTHERAPY | SUPPORTIVE CARE | SINGLE-AGENT | ONCOLOGY | CLINICAL-TRIALS | CISPLATIN PLUS VINORELBINE | QUALITY-OF-LIFE | POLIGLUMEX CT-2103 | MUTATIONS | COOPERATIVE-ONCOLOGY-GROUP | Japan - epidemiology | Lung Neoplasms - drug therapy | Neutropenia - epidemiology | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Lung Neoplasms - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Lung Neoplasms - pathology | Male | Vinblastine - administration & dosage | Infection - etiology | Carboplatin - adverse effects | Neutropenia - complications | Infection - epidemiology | Vinblastine - analogs & derivatives | Vinblastine - adverse effects | Adult | Deoxycytidine - adverse effects | Female | Neutropenia - chemically induced | Paclitaxel - administration & dosage | Carcinoma, Non-Small-Cell Lung - pathology | Drug Administration Schedule | Deoxycytidine - administration & dosage | Carboplatin - administration & dosage | Paclitaxel - adverse effects | Treatment Outcome | Carcinoma, Non-Small-Cell Lung - mortality | Survival Analysis | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Neoplasm Staging | Deoxycytidine - analogs & derivatives | Index Medicus
Journal Article
Journal Article
Journal of Thoracic Oncology, ISSN 1556-0864, 02/2006, Volume 1, Issue 2, pp. 135 - 140
Journal Article